Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/15265161.2022.2075963 | DOI Listing |
Asia Pac J Oncol Nurs
December 2025
Division of Health Sciences, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Objective: To elucidate the current state of coping flexibility and associated factors in gastric cancer patients after gastrectomy.
Methods: A cross-sectional multisite study was conducted with 142 patients with gastric cancer who completed questionnaires on coping flexibility, postgastrectomy dysfunction, health literacy, and perceived social support. Coping flexibility was measured using the Coping Flexibility Scale-Revised, which includes three subscales: Abandonment Coping (i.
Malariaworld J
January 2025
Biosciences Training and Research Unit (UFR), Felix Houphouët-Boigny University, Abidjan, Côte d'Ivoire.
Background: has developed resistance to almost all the antimalarial drugs currently in use. This resistance has been and remains one of the greatest threats to the control and elimination of malaria. The use of molecular markers of resistance to monitor the emergence and spread of antimalarial drug-resistant parasite strains has proved highly effective.
View Article and Find Full Text PDFPediatr Blood Cancer
January 2025
Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
J Med Syst
January 2025
Department of Public Health, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, São Paulo, Brazil.
Directly Observed Treatment (DOT) involves the administration of medication and in-person monitoring by a healthcare team alongside the patient to improve adherence to tuberculosis (TB) treatment. Implementing DOT requires healthcare professionals, transportation, time dedication, and presence at the patient's residence. Meeting all these conditions is not always possible to address the high demand of TB patients who would benefit from this supervision.
View Article and Find Full Text PDFNeurooncol Pract
February 2025
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
The isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, may offer a promising new treatment option for patients with IDH-mutant gliomas. However, the indefinite nature of this targeted therapy raises significant financial concerns. High costs of targeted cancer therapies, often exceeding $150 000 annually, contribute to financial toxicity, characterized by medical debt, income loss, and psychological stress, and place stress on health systems.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!